Business Context and Reporting Period
This Form 8-K is a current report filed by OvaScience, Inc. (noted as Tempest Therapeutics in metadata) on October 24, 2012. The filing discloses the election of a new director and associated compensatory arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It references a prior financing event where the Company issued 6,770,563 shares of Series B preferred stock in March 2012 for an aggregate purchase price of $37,238,096 ($5.50 per share), which converted to common stock on August 13, 2012.
Material Changes
- Board Expansion: The Board of Directors increased its size to eight members.
- Director Election: Thomas Malley was elected as a Class III Director, with a term expiring at the 2015 annual meeting. He was also appointed to the Audit and Compensation Committees.
- Compensation Grant: Mr. Malley received an initial grant of 13,098 nonstatutory stock options at an exercise price of $5.50 per share, vesting monthly over one year. He is also eligible for annual grants of 4,448 options upon continued service.
- Cash Fees: The Board approved annual fees of $30,000 for board service, $8,000 for the Audit Committee, and $5,000 for the Compensation Committee, prorated for 2012.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It notes that Mr. Malley is listed as a Selling Stockholder in the Company's Registration Statement on Form S-1. An indemnification agreement was executed to cover legal expenses and judgments arising from his service as a director.
Investor Verification Checklist
- Verify the total number of outstanding shares and the impact of the Series B conversion on dilution.
- Confirm the vesting schedule and exercise price of the 13,098 options granted to Mr. Malley.
- Review the Form S-1 (File No. 333-183602) for details on Mr. Malley's status as a Selling Stockholder.
- Check the Company's cash position to ensure it can support the new director fees and ongoing operations.